Reforgene wins Best Biopharmaceutical Company of the Year in the healthcare investment awards
On April 3, 2022, Haoyue Capital, a well-known investment bank in China's healthcare industry, officially released the "2022 Sixth Healthcare Investment Excellence List". Reforgene won the "Biopharmaceutical Company of the Year" award. A total of 15 biomedical technology enterprises nationwide were selected in this evaluation.
Reforgene is a leading innovative gene medicine enterprise in China, driven by gene editing technology and dedicated to the birth of novel medicines. It is worth noting that over the past year, Reforgene has also received multiple honors in selection activities hosted by well-known biomedical industry media and institutions, including the 2021 Biopharma Value List "Cell & Gene Therapy TOP10", the 2021 Most Investment-Worthy Emerging BioTech TOP5, and the 2021 China Top 10 Medical Innovation Enterprises, among others.
About the list
As a highly recognized annual authoritative list in the industry, the Healthcare Investment Excellence List has, since its first release in 2017, upheld the principles of fairness, impartiality and objective neutrality. Through the form of real-name voting with "authoritative judges, one vote each", based on publicly disclosed materials and information submitted by various institutions, it comprehensively reviews indicators such as the investment activity, transaction volume, transaction amount and investment returns of healthcare investment funds, and selects the outstanding investment institutions of the year. At the same time, the Excellence List also grants awards to outstanding healthcare enterprises in different fields such as biomedicine, innovative medical devices, in vitro diagnostics, medical services and smart healthcare, aiming to create a truly credible and influential investment list, set new benchmarks for industry development, and create new opportunities for investment cooperation.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.